Effect of Albumin Administration in Hypoalbuminemic Hospitalized Patients With Community-acquired Pneumonia.
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
Community-acquired pneumonia (CAP) remains a leading cause of death world-wide.
Hypoalbuminemia is associated with worse outcomes. However, whether albumin administration
would have a beneficial effect in outcome in patients with CAP remains uncertain.
This project proposes to test the hypothesis of whether the administration of albumin in
hypoalbuminemic patients with CAP would increase the proportion of clinical stable patients
at day 5.
Phase:
Phase 3
Details
Lead Sponsor:
Jordi Carratala
Collaborators:
Institut d'Investigació Biomèdica de Bellvitge Instituto de Salud Carlos III